Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: inborn metabolic disorder therapeutics - Agios Pharmaceuticals

Drug Profile

Research programme: inborn metabolic disorder therapeutics - Agios Pharmaceuticals

Alternative Names: IEM therapeutics - Agios Pharmaceuticals

Latest Information Update: 28 Jul 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Agios Pharmaceuticals
  • Class Small molecules
  • Mechanism of Action Glycolysis modulators; Pyruvate kinase stimulants; Thyroid hormone binding protein stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Phenylketonuria
  • Research Beta-thalassaemia; Friedreich's ataxia
  • No development reported Inborn genetic disorders

Most Recent Events

  • 28 Jul 2018 No recent reports of development identified for preclinical development in Inborn genetic disorders in USA
  • 04 May 2018 Agios Pharmaceuticals plans an IND for Genetic disorders in the fourth quarter of 2018
  • 01 May 2018 Early research in Friedreich's ataxia in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top